Revenue
21 thousand USD
2027 Q2 · USD
Exact inputs and evidence
- Revenue: 21000 USD Source
Market value
$41.52M
8,640,000 shares as of 2026-11-05, at $4.805 a share (IBO, IEX close on 2026-11-12) Primary-source evidence
Annual consolidated revenue for 2026: about USD 32K, using the latest reported figures. The previous period, 2023, was about USD 50K.
Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, over the last 12 months.
Window: transactions dated on or after 2025-11-19.
Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.
21 thousand USD
2027 Q2 · USD
-3,085.71%
2027 Q2 · %
11 thousand USD
2027 Q2 · USD
20000 USD
8544066 shares
-29.88% · -3.64 million shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.
38 thousand USD
2025-10-01 – 2026-09-30
1.61 million USD
2025-10-01 – 2026-09-30
116 thousand USD
2025-10-01 – 2026-09-30
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-11-18.
Financial data available through: 2025-12-31.
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Prior period
−USD 24.71 million
–
Current period
−USD 11.84 million
–
-11838000 − -24708000 = 12870000 USD
-24708000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-11838000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceThe citation records this snapshot. The page link may show a newer release later.
Prior period
−USD 2.85 million
–
Current period
−USD 1.89 million
–
-1890000 − -2854000 = 964000 USD
-2854000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-1890000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceThe citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Revenue, Capital expenditure.
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
| Period | Revenue | Operating costs | Operating income | Tax, interest and other | Net income | Free cash flow | Source |
|---|---|---|---|---|---|---|---|
| 2023 2022-01-01 – 2022-12-31 | 50000 | 3454000 Derived | -3404000 | 3851000 Derived | -7255000 | Unavailable | Source
|
| 2026 2025-01-01 – 2025-12-31 | 32000 | 4314000 Derived | -4282000 | 7556000 Derived | -11838000 | Unavailable | Source
|
Amounts are exact, in USD.
Sales over time and how quickly they are changing.
Revenue reported for each complete financial period.
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2023 | Revenue | 50000 |
|
| 2026 | Revenue | 32000 |
|
Change in revenue from the same financial period one year earlier.
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2023 | Year over year | No prior comparable period |
|
| 2026 | Year over year | No prior comparable period |
|
How much revenue becomes profit, and how much cash operations generate.
Operating income, net income and free cash flow as a share of revenue.
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2023 | Operating margin | -6,808% |
|
| 2026 | Operating margin | -13,381.3% |
|
| 2023 | Net margin | -14,510% |
|
| 2026 | Net margin | -36,993.8% |
|
| 2023 | Free cash flow margin | Not reported |
|
| 2026 | Free cash flow margin | Not reported |
|
Cash generated by the company’s normal business operations.
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2023 | Operating cash flow | -2242000 |
|
| 2026 | Operating cash flow | -1890000 |
|
Operating cash flow minus capital expenditure for the same period and unit.
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2023 | Free cash flow | Unavailable |
|
| 2026 | Free cash flow | Unavailable |
|
Liabilities and short-term ability to meet obligations at each period end.
Total liabilities as a share of total assets.
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2023 | Liabilities / assets | 29.7% |
|
| 2026 | Liabilities / assets | 10.6% |
|
Current assets divided by current liabilities.
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2023 | Current assets / current liabilities | 0.01× |
|
| 2026 | Current assets / current liabilities | 0.35× |
|
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2022 2021-01-01 – 2021-12-31 | −USD 1.3 million Exact valueExact value: -1303000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 2.03 million Exact valueExact value: -2027000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2023 2022-01-01 – 2022-12-31 | −USD 7.26 million Exact valueExact value: -7255000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 2.24 million Exact valueExact value: -2242000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2024 2023-01-01 – 2023-12-31 | −USD 4.34 million Exact valueExact value: -4336000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 2.85 million Exact valueExact value: -2851000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2025 2024-01-01 – 2024-12-31 | −USD 24.71 million Exact valueExact value: -24708000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 2.85 million Exact valueExact value: -2854000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2026 2025-01-01 – 2025-12-31 | −USD 11.84 million Exact valueExact value: -11838000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 1.89 million Exact valueExact value: -1890000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
19 filings · 1,033 latest values · 1,033 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001834105, 1834105, IBO, edgar:1834105
Also known as IMPACT BIOMEDICAL INC., Impact BioMedical, INC.